All News
Filter News
Found 100 articles
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
9/8/2021
Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.
-
BioSpace Movers & Shakers, Feb. 12
2/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Cerevance Appoints Naidong Ye, Ph.D., As Vice President and Head of Chemistry, Manufacturing and ControlsWill lead scale-up and production as Cerevance advances multiple clinical-stage programs
2/10/2021
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Cerevance Appoints Carrie Ann Cook As Chief Business Officer
2/1/2021
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer effective February 1, 2021
-
Biopharma Executive Perspectives on 2021
1/11/2021
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay. -
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.
-
BioSpace Movers & Shakers, Dec. 11
12/11/2020
Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Cerevance Appoints David Lubner to Board of DirectorsLife sciences industry veteran brings more than 25 years of financial and operational experience
12/8/2020
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors. Mr. Lubner most recently served as executive vice president and chief financial officer of Ra Pharma, which was acquired by UCB in April of this year. Before joining Ra Pharma, he served
-
Despite a number of anti-psychotic medications available, there are no approved drugs to address underlying cognitive development issues. Cerevance aims to change that.
-
Clinical Catch-Up: November 16-20
11/23/2020
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look. -
Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition StudyPositive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia
11/16/2020
Cerevance, a private drug discovery and development company focused on brain diseases, today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).
-
Ebb Therapeutics® Brings To Market A New Cutting-Edge Sleep Wearable
9/21/2020
The sleep tech company's CoolDrift™ Versa™ device is clinically-validated to calm racing mind, enabling relaxation and better-quality sleep [21-September-2020] PITTSBURGH , Sept. 21, 2020 /PRNewswire/ -- Ebb Therapeutics ® (Ebb) today announced the launch of the CoolDrift™ Versa™ (Versa™), the company's second clinically-validated sleep wearable that leverages excl
-
Cerevance Expands Series B Financing to $65 MillionIncreases Funds to Develop Therapeutics Acting on Novel Targets for Brain Diseases
7/21/2020
Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April. With this second closing, UPMC Enterprises, Casdin Capital and Dolby Family Ventures joined the company’s investor base, while Foresite Capital added to its investment made in the first closing. Cerevance’s previous closing also included GV (formerly Google Ve
-
SleepScore Labs Adds State of the Art Ebb® CoolDrift™ to Scientifically Validated Collection of Sleep Solutions
6/25/2020
SleepScore Labs confirms Ebb® CoolDrift™ technology helps people experiencing sleeplessness reach deeper, more restorative sleep faster
-
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Di...
-
Sleep Tech Company Ebb Therapeutics™ Appoints Dr. Michael Breus as a Sleep Advisor
6/4/2020
Ebb Therapeutics ™ (Ebb) has announced that world-renowned sleep expert Dr. Michael Breus will serve as a Sleep Advisor to the brand. In this role, Dr. Breus - whose expertise in
-
Cerevance secured $45 million in a Series B financing round to support the development of its therapeutics for central nervous system diseases, including Alzheimer’s and Parkinson’s disease.
-
Cerevance Closes $45 Million Series B FinancingProceeds to Fund a Diverse Pipeline of Therapeutics Acting on Novel Targets for Brain Diseases
4/14/2020
Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors, which include Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceutical Company, Ltd., the Dementia Discovery Fund and Lightstone Ventures. Cere